Vaccine Race: Mei Mei Hu on Developing, Researching a COVID-19 Vaccine

Podcast

A vaccine developer joins for a firsthand discussion on the development, research, and distribution process.

Episode highlights

0:17 It’s IDWeek!
3:00 Contagion® COVID-19 Vaccine Tracker Update
6:00 Introducing Mei Mei Hu
7:12 The young history of Covaxx
7:45 The vaccine launch process
9:33 What is the UB-612 platform?
11:33 Current research
13:34 Concerns over rapid COVID-19 vaccine development?
18:25 Manufacturing needs
20:23 What are the barriers?
23:00 Outro

Today marks the beginning of IDWeek 2020, as the global-scale infectious disease meeting has been forced to resort its comprehensive clinical agenda to a virtual format due to coronavirus 2019 (COVID-19).

As an acknowledgement to the great burden of COVID-19—and in spirit with the meeting’s great collaborative efforts—the first 24 hours of the annual meeting are dedicated to discussions around the pandemic, titled “Chasing the Sun.”

While Contagion® will provide around-the-clock IDWeek 2020 coverage over the next days, we kick off our content in a similar fashion: the second episode of our limited series podcast Vaccine Race.

In this episode, senior editor John Parkinson sits down with Mei Mei Hu, co-chief executive officer of vaccine development company Covaxx, and honorary member of Time Magazine’s Next 100 List of 2019.

Covaxx’s investigational COVID-19 vaccine, UB-612, is the first multitope peptide-based vaccine capable of activating both B-cells and T-cells.

Hu spoke to Contagion about her company and its creation of this interesting candidate, and provided some firsthand insights into getting a vaccine through the development process.

Stay tuned for more IDWeek 2020 content, and a new Vaccine Race episode, throughout the week.

Newsletter

Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.

Recent Videos
© 2025 MJH Life Sciences

All rights reserved.